Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06842407

Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy Donors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy

Location status: Recruiting

Location contact

Daniele Prati, MD

CONTACT

[email protected]

0039 0255034687

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • blood donors
  • age of 18 years or more
  • able to sign informed consent

Exclusion criteria

  • age below 18 years
  • Positive for HIV, HCV, HBV
  • not suitable for blood donation
  • not able to understand or sign informed consent

Treatment and study plan

Primary outcomes

  1. Validation of molecular targets for immunotherapy

    Time frame: 04.2023-06.2026

  2. Selection of therapeutic antibodies

    Time frame: 04.2023-06.2026

Secondary outcomes

  1. Set up of immunological assays to adress monoclonal antibodies mechanism of action

    Time frame: 04.2023-06.2026

Study contacts

Contact information is provided by the study sponsor or research team.

Renata M Grifantini, PhD

CONTACT

[email protected]

0039 00660220

Sponsors and collaborators

Lead sponsor

Checkmab S.r.l.

Industry

Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Registry information

Official study title

Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

Acronym: Immuno-ab

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2025
Registry last updated
Feb 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.